{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/Praxis-Precision-Medicines-Announces-Extension-Period-for-Relutrigine-for-Treatment-of-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies.html", "message": "News view counter 821336 successfully enlarged"}